News

8. April 2024

Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting

Read Article

11. December 2023

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform

Read Article

3. November 2023

Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting

Read Article

16. October 2023

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

Read Article

25. September 2023

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Read Article

7. September 2023

DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers

Read Article

17. April 2023

Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting

Read Article

17. January 2023

Glycotope Presents Glyco-Engineered Cell Lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium

Read Article

13. December 2022

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Read Article

8. November 2022

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting

Read Article